Benign diseases of the breast: essential mastodinia; mastodinia associated with benign breast disease (complex treatment of benign mastopathy on the background of progesterone insufficiency). Prozhestozhel is not indicated for use in men.
Main active ingredient: progesterone.
Excipients included in the preparation: octyldodecanol, carbomer, castor oil, ethanol, purified water.
It is produced in the form of a gel in tubes of 80 grams. A gram of gel contains 10 mg of progesterone.
This pharmaceutical agent belongs to hormonal progestogen preparations used in mammology for topical use.
The main active ingredient is progesterone. This is a hormone of natural origin, produced in women with the help of the so-called “yellow body” – one of the most important progesterone receptors in the female body. A particularly large amount of this hormone is produced in women in the placenta during pregnancy, during the period that begins at the end of the first trimester.
Has the ability to bind selectively to progesterone receptors. It is an agonist of many membrane receptors. Able to stimulate some liver enzymes.
When treated with microdoses of natural progesterone, it is highly effective, with no masculine effects and no effect on the lipid profile after estrogens are administered.
When applied topically, getting into the breast tissue, the drug has the property of reducing capillary permeability and the activity of connective tissue edema, thereby preventing the likelihood of proliferation.
This drug Progestogel is used in the treatment of female genital diseases associated with a lack of progesterone.
In particular, they are used in the treatment of:
- mastodynia, incl. essential;
- benign mastopathy (with progesterone deficiency).
The drug in question is contraindicated for use in cases where the patient has severe hypersensitivity (allergy) to the main or to one of the auxiliary components.
Use is contraindicated in:
- breast cancer;
- nodular forms of fibrocystic mastopathy;
- tumors (tumor-like formations) of the mammary gland of unknown etiology;
- genital cancer (as monotherapy).
Not intended for intravaginal administration. It is not a contraceptive!
Application during pregnancy and lactation
This drug can be used in the treatment of pregnant women only as directed by a doctor.
If it is necessary to administer the drug during breastfeeding, then lactation should be suspended for the duration of treatment.
Method of administration and dosage
Progestogel is intended for external use – applied to the skin of the mammary glands.
One dose of 2.5 grams of gel is applied once a day to the surface of the skin and rubbed in until completely absorbed.
The maximum dose per day is 5 grams of gel.
Treatment usually lasts no less than 3 months. The dosage, treatment regimens, duration of the course of treatment are determined and can be adjusted individually by the attending physician, depending on the indicators of a particular patient.
Overdose is unlikely due to the lack of entry into the systemic circulation and the lack of drug toxicity.
In case of accidental overdose, symptomatic treatment is recommended.
The drug is well tolerated.
Possible side effects in violation of the barrier functions of the skin, since in this case there is a risk of developing systemic side effects. In particular, there may be:
- menstrual irregularities, amenorrhea;
- breakthrough bleeding;
- soreness of the mammary glands;
- “Hot flashes”;
- decreased libido;
- hypersensitivity reactions, incl. erythema at the site of application of the gel;
- swelling of the lips and neck (angioedema);
- fever, headache, nausea.
Storage conditions and periods
Expiration date – up to 3 years from the production date indicated on the package.
Storage temperature Progestogel – no more than 25 ° C.